Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

Background:The mainstays of treatment for pulmonary disease caused by opportunist mycobacteria are rifampicin (R) and ethambutol (E). The role of macrolides, quinolones and immunotherapy with Mycobacterium vaccae is not clear. A trial was undertaken to compare clarithromycin (Clari) and ciprofloxaci...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thorax 2008-07, Vol.63 (7), p.627-634
Hauptverfasser:	Jenkins, P A, Campbell, I A, Banks, J, Gelder, C M, Prescott, R J, Smith, A P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anti-Bacterial Agents - therapeutic use Antitubercular Agents - therapeutic use Bacterial diseases Bacteriology Biological and medical sciences Cardiology. Vascular system Chemotherapy Ciprofloxacin - therapeutic use Clarithromycin - therapeutic use Disease Drug Therapy, Combination Ethambutol - therapeutic use Family physicians Female Human bacterial diseases Humans Immunotherapy Immunotherapy - methods Infectious diseases Laboratories Male Medical sciences Middle Aged Mycobacterium Mycobacterium vaccae Opportunistic Infections - mortality Opportunistic Infections - therapy Patients Pneumology Rifampin - therapeutic use Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - mortality Tuberculosis, Pulmonary - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!